Magnetic Resonance Imaging Using Ferumoxtran-10 in Finding Metastases to the Axillary Lymph Nodes in Patients With Breast Cancer

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically or cytologically confirmed invasive breast cancer
• •Candidate for sentinel lymph node biopsy and/or axillary lymph node dissection
• •Hormone receptor status:
• •* Not specified
• •PATIENT CHARACTERISTICS:
• •Age
• •18 and over
• •Sex
• •Male or female
• •Menopausal status
• •Not specified
• •Performance status
• •Not specified
• •Life expectancy
• •Not specified
• •Hematopoietic
• •WBC ≥ 3,000/mm\^3
• •Absolute neutrophil count ≥ 1,500/mm\^3
• •Platelet count \> 100,000/mm\^3
• •Ferritin ≤ 350 ng/mL\*
• •Transferrin saturation level ≤ 40%\* NOTE: \*Patients with lab values above these limits may be eligible provided there is no hemochromatosis by hematology consultation
• •Hepatic
• •Bilirubin normal
• •AST and ALT ≤ 2.5 times upper limit of normal
• •Alkaline phosphatase normal
• •PT normal
• •Albumin normal
• •No history of cirrhosis
• •Renal
• •Creatinine normal OR
• •Creatinine clearance \> 60 mL/min
• •Cardiovascular
• •No symptomatic congestive heart failure
• •No unstable angina pectoris
• •No cardiac arrhythmia
• •Other
• •Not pregnant or nursing
• •Negative pregnancy test
• •Medically stable
• •No ongoing or active infection
• •No history of allergic reaction attributed to compounds of similar chemical or biological composition to ferumoxtran-10 (e.g., iron preparations, parenteral iron, parenteral dextran, parenteral iron-dextran, or parenteral iron-polysaccharide preparations)
• •No history of allergic reaction to any contrast media
• •No immunodeficiency that would predispose patient to a specific or non-specific mediator release
• •No contraindication to MRI, including any of the following:
• •* Severe claustrophobia
• •* Pacemaker
• •* Aneurysm clips
• •* Defibrillators
• •* Certain types of replacement joints
• •* Other institutional contraindication to MRI
• •No psychiatric illness or social situation that would preclude study compliance
• •No other uncontrolled illness
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy
• •Not specified
• •Chemotherapy
• •Not specified
• •Endocrine therapy
• •Not specified
• •Radiotherapy
• •Not specified
• •Surgery
• •Not specified
• •Other
• •More than 30 days since prior investigational agents
• •More than 3 months since prior ferumoxides